E2F2 was also observed to be upregulated in astrocytomas, and more importantly, it exhibited a distinctive expression in CD133‐positive cells which are considered to be enriched in glioma stem‐like cells (Okamoto et al., 2007). This evidence concerns the gene E2F2 and central nervous system cancer.